UPDATE 2: US: Pfizer seeks "maximum value" from baby food unit
US pharmaceutical group Pfizer has insisted it will get maximum value for its shareholders out of any move to separate its infant nutrition business.
"The nutrition business is a highly-valued asset, and our decision about strategic options will be driven by value creation for the business and delivering the best after-tax value for our shareholders," a spokesperson for the company told just-food today (18 April).
Reports have suggested that Pfizer is nearing a deal to sell its infant nutrition unit for US$9-10bn.
Pfizer declined to comment directly on the reports. However, the spokesperson added "no decisions have been made" and insisted the group is in the "ongoing" process of "exploring strategic alternatives" for the unit.
When contacted by just-food Nestle declined to comment, while Danone was not immediately available for comment.
Last week brought further evidence of the difficulties facing food manufacturers as they look to grow their businesses in the developed markets of the US and Europe....
- M&A Watch: Raisio should sell to private equity
- Infographic: Snapshot of Japan's food sector
- On the money: Solid Lindt outpaces chocolate peers
- Spotlight: What could be impact of Russia's ban?
- Briefing: Expansion agenda of Japan's food majors
- Russian government eases ban on food imports
- Pork Farms buys Kerry Group's pastry plants
- Kerry cools claim spreads move could hit jobs
- Profits up at chocolate group Lindt
- Japan's Sanyo takes stake in Olam's food biz
- New Strategies for offering Convenience in Food - targeting new occasions, best practice and new solutions
- David Chapman's Ice Cream Ltd in Packaged Food (Canada)
- Global Bakery & Cereals Market: Merger and Acquisitions May 2014
- Food Retail: Top 5 Emerging Markets Industry Guide
- Other Dairy in Russia